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1. Introduction
  Peripheral neuropathy is a problem with the nerves that 
can produce pain, loss of sensation, and an inability to 
control muscles. Complaints of pain, sensation of “pins 
and needles,” numbness, and tingling are frequent 
in the distribution of the affected nerve. Peripheral 
neuropathy, associated with diabetes mellitus (DM), 
neurotoxic chemotherapy, human immunodeficiency virus/
antiretroviral drugs, alcoholism, nutrient deficiencies, heavy 
metal toxicity, and other etiologies, results in significant 
morbidity[1]. Conventional pain medications primarily mask 
symptoms and have significant side effects and addiction 
profiles. At the same time, widening body of research 
indicates medicine from natural source may offer significant 
benefit to this patient population. 
  Trigonella foenum-graecum L. (Fabaceae), also known as 
fenugreek, is one of the oldest medicinal plants, and has 
a long history of medical uses in Ayurvedic and Chinese 
traditional medicine. There are several reports concerning 
the anti-inflammatory, antipyretic and antinociceptive 
effects of the fenugreek in traditional medicinal literature[2] 
and use of fenugreek for relieving skin inflammation 
is approved by many regulatory agencies e.g. German 
Commission E[3]. Fenugreek leaves were reported to be 
potent anti-inflammatory[4] and analgesic[5] properties in 
animal models of inflammation and pain respectively. These 
effects are attributed to alkaloid content of fenugreek[6]. 
  Trigonelline (N-methylnicotinic acid) is a major alkaloid 
of fenugreek seeds along with other constituents like 
4-hydroxyisoluecine, and galactomannans[7,8]. Trigonelline 
is shown to be potent antidiabetic[9] and antioxidant[10] 
compound. Therefore, fenugreek extract standardized to 
bioactive marker compound, trigonelline can prove to be 
beneficial in management of neuropathic pain.  
  The fenugreek seed extract (IND01) has been shown to 
be effective in animal models of DM[7,11,12]. Moreover, its 
major alkaloid, trigonelline, showed anti-diabetic effects 
in animal models and patients[13] of DM. However, IND01 
or trigonelline, is not yet evaluated in management of 
neuropathic pain. Therefore, the objective of the present 
work was to standardize the fenugreek extract (IND01) for 
the marker compound, trigonelline and to evaluate its 
effects in the animal models of peripheral neuropathic pain.
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Objective: To evaluate the effects of the standardized extract of fenugreek (Trigonella 
foenum-graecum L. Family: Leguminasae) seed (IND01) in animal models of peripheral 
neuropathy. Methods:  IND01 was prepared from fenugreek seeds and standardized by high 
performance liquid chromatography to a marker compound, trigonelline. The effects of daily oral 
administration of IND01 (50, 100 and 200 mg/kg) were studied in rats after partial sciatic nerve 
ligation (PSNL) and sciatic nerve crush injury (SNCI) during 30-days period. The measurements 
on thermal hyperalgesia (TH), motor function test (MFT) score and motor nerve conduction velocity 
(MNCV) were recorded. Results: IND01 offered sustained protection against TH and deranged MFT 
scores in both models from 7-day onwards. Fifteen days of daily oral administration of IND01 
restored MNCV reduction in rats with SNCI but not with PSNL. Conclusions: IND01 was found to 
be effective in rat models of painful peripheral neuropathy. 
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2. Materials and methods
2.1. Animals 
  Male Wistar rats (150-200 g) were purchased from National 
Toxicology Centre, Pune. During the experiment, rats were 
housed at standard housing condition like temperature of (25
依1) 曟, relative humidity of 45%-55% and 12 h light: 12h dark 
cycle. Rats had free access to food pellets (Navmaharashtra 
Chakan Oil Mills Ltd., Sangli, India) and tap water ad libitum 
during the experiments. All experiments are in accordance 
with ethical guidelines for investigations of experimental 
pain in conscious animal. Research protocol was approved 
by Institutional Animal Ethics Committee of Poona College 
of Pharmacy, Bharati Vidyapeeth Deemed University, Pune.
2.2. Chemicals
  Pyridoxine hydrochloride (HCl) (Sigma-Aldrich, USA) and 
anaesthetic ether (TKM Pharma, Hyderabad, India) were 
purchased from respective vendors. All other chemicals 
were of analytical grade. The seeds collected in the areas of 
State of Rajasthan in India during November 2006 were used 
in the preparation of test compound, IND01. The seeds were 
authenticated by Dr. A. M. Mujumdar, Agharkar Research 
Institute, Pune, India and voucher specimen was deposited 
at that Institute. 
2.3. Extraction and standardization 
  The IND01 is an Trigonella foenum-graecum seed extract 
and prepared by reported procedure[14]. Briefly, Fenugreek 
seeds (1 000 g) purchased locally were flaked to a thickness 
of 5 mm, loaded in an extractor and water: alcohol (30:70) 
was circulated in the extractor at room temperature for 8 
h. The extract was drained and distilled to remove alcohol. 
The marc was extracted with hexane (5 L) to remove oil and 
other lipids. The oil free water extract was passed through 
strong acid cation exchange resin in gel (500 mL). The resin 
was thoroughly washed with de-ionized water to remove 
adhering sugars and other contaminants. The column 
was eluted with 10% aqueous ammonia. The solution was 
concentrated to remove ammonia and water. The resulting 
powder (IND01) was made free flowing using spray drying 
process and used for further study (Yield: 9.0 g, 0.9% w/w). 
  The standardization of IND01 was done on the marker 
compound, trigonelline by HPLC as follows: 50 mg of IND01 
powder was dissolved in 100 mL demineralized water with 
stirring. The solution was filtered through Whatman filter 
paper (#41) and injected in HPLC system. Similarly, the 
preparation of reference standard of trigonelline HCl (Sigma-
Aldrich, USA, ≥ 98.0% ) was prepared with 10 mg dissolved 
in 100 mL of demineralized water. The HPLC conditions 
were as follows: Model–JASCO LC 2000 with UV-2075; 
Column: Reverse phase C-18 column L1 (250 mm 伊 4.6 mm, 
particle size of 5 毺m); Detector: UV-VIS; Mobile phase: 
trifluroacetic acid (60) with water: acetonitrile mixture (40). 
Injection volume: 20 毺L, Method time: 30 mins, Flow rate: 
1.5 mL/min; Detector : UV (at 254 nm). The area under the 
curve (AUC) was recorded from the resultant chromatogram 
and content of marker compound (trigonelline HCl) was 
calculated.  Solutions of IND01 were freshly prepared in 
distilled water and was administered as mg per kg basis for 
further evaluation in experimental animals.
2.4. Induction of mononeuropathy caused by partial sciatic 
nerve ligation (PSNL) in rats
  The neuropathic pain was produced in rats by PSNL 
according to reported procedure[15]. On baseline (day 0), the 
rats were divided into following groups of 6 rats each(栺)
vehicle control (栻) sham control (栿) PSNL control and (桇)
IND01 (50 mg/kg, p.o.) (桋) IND01 (100 mg/kg, p.o.) and (桍)
IND01 (200 mg/kg, p.o.) treated (桏)  pyridoxine HCl
(100 mg/kg, p.o.) group. In rats of group-栿, 桇, 桋, 桍 and 桏,
the right sciatic nerve was exposed and underwent partial 
injury with the help of silk suture. In rats of group 栻 (sham 
control), exposure of nerve was conducted but PSNL was not 
done. After surgical procedures, the wounds were aseptically 
closed with sutures. In rats of group 栺 (vehicle control), 
no surgical procedure was performed. Sciatic nerve of left 
leg was kept untouched in all rats. Rats were treated with 
antibiotics and returned to their cages and allowed to recover 
after surgery for 2 days. After recovery, rats from group 栺,栻 
and 栿 were treated with once daily administration of distilled 
water for next 30 days. Rats from group 桇, 桋, 桍 and 桏
received once a day treatment of IND01 (50 mg/kg, p.o.), IND01 
(100 mg/kg, p.o.), IND01 (200 mg/kg, p.o.) and pyridoxine HCl 
(100 mg/kg, p.o.) respectively for next 30 days. 
2.5. Induction of mononeuropathy caused by sciatic nerve 
crush injury (SNCI) in rats
  SNCI was induced in rats according to reported 
method[16] and its modification[17]. The rats were 
divided into following groups of 6 rats each (栺) vehicle 
control (栻) sham control (栿) SNCI control and (桇)
IND01 (50 mg/kg, p.o.) (桋) IND01 (100 mg/kg, p.o.) and (桍)
IND01 (200 mg/kg, p.o.) treated groups (桏) pyridoxine HCl 
(100 mg/kg, p.o.). In rats of group-栿, 桇, 桋,桍 and 桏, the 
right sciatic nerve was exposed at high thigh level under 
ether anaesthesia and aseptic conditions and was crushed 
using a aneurysm clip twice for 30 s with an interval of 60 s 
between. In rats of group 栻 (sham control), the sciatic nerve 
was explored but not crushed performed. After surgical 
procedures, the wound closure and recovery procedure, 
treatments and measurements were as per repeated as 
performed in PSNL model.
2.6. The measurements 
  The parameters of the pain related parameters were 
recorded daily in the morning (10 am to 12 pm) and doses 
were administrated immediately afterwards. Measurement of 
thermal hyperalgesia (TH) was done using principle of Eddy 
and Leimbach using  hot-plate method[17]. A plastic cylinder 
was used to confine the rats on the electrically heated 
surface of the hot-plate analgesiometer (Ugo Basile, Versace, 
Italy) which was maintained at (55.0±0.5) 曟. The rats were 
individually placed on the heated plate and the time was 
recorded when either licking of hind paw or jumping (pain 
latency) occurs. Time for pain latency was recorded on day 
0, 2, 7, 14, 21, 28 following treatment. A cut off time of 22 
seconds was adopted to avoid tissue injury. 
  Motor functions test (MFT) were measured by scoring 
Aashish S Morani et al./Asian Pacific Journal of Tropical Medicine (2012)385-390 387
spontaneous gait and hind paw posture at three 5-minutes 
(300 sec.) interval (total-15 min) by reported method[18]. The 
rats were placed in the plexiglass chamber and allowed 
to acclimatize before the observation period. Each rat was 
individually observed for three 5-minutes (300 sec.) interval 
(total-15 min). The positions of the lesioned hind paw were 
graded between 0-5. Each rat was scored 3 times and mean 
was calculated. The observations were made on day 0, 2, 15 
and 30. Based on the grading, the MFT score was determined 
as per following formula: MFT score =  [1(T1) + 2(T2) + 3(T3) + 
4(T4) + 5(T5)] / 300. MFT is a measure of Pain. More the MFT 
score, more is the pain. 
  Measurement of motor nerve conduction velocity (MNCV) 
was performed in rats on 15th day after PSNL or SNCI as 
per reported method[18,19]. Rats were anesthetized and hairs 
form dorsal side of rats paws were shaved with hair remover 
cream. The paws of rats were cleaned using a moist cotton 
plug. MNCV was recorded by stimulating the sciatic and 
tibial nerves at sciatic and tibial notch respectively. The 
recording specification: stimulator (Weltronics India), pulse 
(0.1 ms square wave), with a  pair of monopolar needle 
electrodes (1.0-1.5 mA, 2.0 mV/D). Responses were recorded 
from the plantar muscles using data acquisition system 
(Biopac, Santa Barbara, CA, USA). MNCV was determined 
using following formula: MNCV (m/s) =  [Distance between 
the sciatic and tibial stimulation points (in m)]/ [latency for 
sciatic (in s) -latency for tibial (in s)].
2.7. Statistical analysis 
  Data for TH was expressed as mean pain latency in 
paws (in s) ± SEM and was analyzed by two-way repeated 
measures ANOVA followed by post hoc Bonferroni test for 
comparison of groups. MFT and MNCV data was expressed 
as mean parameter value (in s) ± SEM. The data for MFT was 
analysed by two-way repeated measures ANOVA followed 
by Bonferroni test for comparison of groups. MNCV data 
was analysed by one-way ANOVA followed by Dunnett’s 
multiple comparison test for comparison of groups.
3. Results 
3.1. Standardization 
  At wavelength of 254 nm, the HPLC of sample of IND01 
showed presence of the marker compound, trigonelline 
HCl, at retention time of 1.750 with AUC = 14 704.3 (Figure 
1). The reference standard of trigonelline HCl showed peak 
at retention time 1.775 min with AUC = 15 922.2 (Figure 1). 
The concentration of trigonelline in the sample of IND01 was 
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Figure 1. The HPLC fingerprint of (A) IND01 (retention time = 1.750) 
and (B) reference standard (retention time = 1.775) at wavelength of 
254 nm for detection of the marker compound, trigonelline HCl.
3.2. Effect on TH in Hot-plate test after PSNL in rats
  No significant change was observed in mean paw 
withdrawal latencies in normal and sham control rats 
during the study period (Table 1). PSNL in rats resulted in 
significant (P < 0.001) decrease in mean paw withdrawal 
latencies on day-2 till day-14 as compared with normal or 
sham control rats confirming TH (Table 1). The reduction 
in paw withdrawal latencies were significantly reversed by 
daily treatment of IND01 (50, 100 or 200 mg/kg, p.o.) and 
pyridoxine HCl (100 mg/kg) on day-2 days and onwards 
(Table 1). 
Table 1
Effect of IND01 on mean pain latency (sec.) against TH in hot-plate test after PSNL in rats.
Group
Mean pain latency (sec)  依  SEM
Day 0 Day 2 Day 8 Day 14
Normal 10.02 依 0.44 10.37 依 0.35 9.62 依 0.42 10.65 依 0.34
Sham control   9.93 依 0.35   7.63 依 0.37 9.17 依 0.15 10.40 依 0.22
PSNL control 10.43 依 0.30         3.28 依 0.15###, $$$       3.67 依 0.13###,$$$         3.82 依 0.15###,$$$
IND01 (50)  + PSNL   9.63 依 0.39   3.80 依 0.25 4.03 依 0.14   4.52 依 0.17
IND01 (100) + PSNL 10.13 依 0.39    4.30 依 0.25*    8.03 依 0.14***       9.52 依 0.17***
IND01 (200) + PSNL 10.43 依 0.30      4.98 依 0.11***    8.10 依 0.08***       8.75 依 0.18***
Pyridoxine HCl (100) + PSNL 10.00 依 0.56     4.53 依 0.18**    8.68 依 0.11***       9.92 依 0.14***
Data was expressed as mean pain latency in paws with PSNL (in seconds) 依 SEM for six rats per group. Data was analyzed by two-way repeated 
measures ANOVA followed by post hoc Bonferroni test for comparison of groups. ## P < 0.01 and ### P < 0.001 as compared with normal rats. $$$ P 
< 0.001 as compared with sham control group. * P < 0.05, ** P < 0.01, *** P < 0.001 as compared with PSNL control group.
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3.3. Effects on MFT score after PSNL in rats
  No significant change was observed in MFT scores 
(spontaneous gait and hind paw posture) in normal and 
sham control rats during the study period (Table 2). PSNL 
increased the MFT score significantly (P < 0.001) compared 
with normal or sham control rats (Table 2). In PSNL rats, 
MFT score was significantly increased on day-2 (2.92) and 
reached to 2.98 (day-15) and 3.02 (day-30) indicating more 
pain. PSNL-induced increase in MFT score was prevented 
by daily treatment of IND01 (100 and 200 mg/kg) for 15 
days onwards whereas pyridoxine HCl (100 mg/kg) showed 
significant (P < 0.01) prevention of MFT score on day-2 and 
onwards. Daily treatment of IND01 (50 mg/kg, p.o.) did not 
alter the MFT score as compared to PSNL control rats (Table 
2).
3.4. Effect on MNCV after PSNL in rats
  The MNCV in normal and sham control rats was found to 
be 53.14 and 46.89 m/s respectively as observed on day-15 
of the study (Table 2). PSNL control rats showed MNCV of 20 
m/s, which is significantly (P < 0.001) less as compared with 
normal or sham control rats (Table 2) indicating neuropathy 
induction. Treatment of IND01 (50, 100 or 200 mg/kg) for 15 
days did not change MNCV as compared with PSNL control 
rats (Table 2). On 15-days of treatment, pyridoxine (100 mg/
kg, p.o.) showed MNCV of 31.25 m/s, which was significantly 
(P < 0.01) more compared with MNCV of PSNL control rats 
(Table 2). 
3.5. Effect on TH in hot-plate test after SNCI in rats
  The mean paw withdrawal latencies in normal rats were 
in the range of 10.97 to 11.87 s and that of sham control rats 
were 9.55 to 11.92 s during the study period (Table 3). SNCI in 
rats resulted in significant (P < 0.001) decrease in mean paw 
withdrawal latencies on day-2 onwards compared to normal 
or sham control rats confirming TH (Table 3). Mean paw 
withdrawal latencies after daily treatment of IND01 (100 and 
200 mg/kg) or pyridoxine (100 mg/kg) were significantly (P < 
0.001) more compared to mean paw latencies of SNCI control 
rats on 7-days of treatment (Table 3). IND01 (50 mg/kg, p.o.) 
group showed mild and significant (P < 0.05) increase in paw 
withdrawal latencies on 14-days treatment (Table 3).
3.6. Effect on MFT score after SNCI in rats 
  No significant change was observed in MFT scores 
(spontaneous gait and hind paw posture) in normal and sham 
control rats during the study period (Table 4) indicating 
induction of neuropathy. SNCI increased the MFT score 
significantly (P < 0.001) as compared with normal or sham 
control rats (Table 4). In SNCI rats, MFT score was increased 
from 2.92 (on day-2) to 2.98 and 3.03 (on day-15 and day-
30) respectively. SNCI-induced increase in MFT score was 
prevented by daily treatment of IND01 (50, 100 and 200 mg/kg)
or pyridoxine HCl (100 mg/kg) for 15 days onwards. On 
Table 2
Effect of IND01 on MFT score and MNCV after PSNL in rats
Group 
MFT score依 SEM MNCV (m/s)
Day 15Day 0 Day 2 Day 15 Day 30
Normal 0.00 依 0.00 0.00 依 0.00 0.00 依 0.00 0.00 依 0.00 53.14 依 4.01
Sham control 0.00 依 0.00 0.27 依 0.05 0.09 依 0.03 0.10 依 0.02 46.89 依 1.58
PSNL control 0.00 依 0.00       2.92 依 0.08###, $$$       2.98 依 0.20###, $$$        3.02 依 0.07###, $$$        20.00 依 0.77###, $$$
IND01 (50) + PSNL 0.00 依 0.00 3.06 依 0.06 2.99 依 0.04  3.19 依 0.04 22.20 依 0.89
IND01 (100) + PSNL 0.00 依 0.00 2.91 依 0.11    1.99 依 0.04***     1.99 依 0.04*** 22.95 依 0.89
IND01 (200) + PSNL 0.00 依 0.00  2.71 依 0.11*   1.98 依 0.06**     1.98 依 0.06*** 23.75 依 0.96
Pyridoxine HCl (100) + PSNL 0.00 依 0.00   2.63 依 0.06**    1.09 依 0.03***     1.09 依 0.03***    31.25 依 1.42**
Data was expressed as mean parameter value (in seconds) 依 SEM for six rats per group. Data for MFT was analyzed by two-way repeated 
measures ANOVA followed by post hoc Bonferroni test for comparison of groups. Data for MNCV was analyzed by one-way ANOVA followed by 
post hoc Dunnett's multiple comparison test for comparison of groups. ### P < 0.001 as compared with normal rats. $$$ P < 0.001 as compared 
with sham control group. * P < 0.05, ** P < 0.01, *** P < 0.001 as compared with PSNLcontrol group.
Table 3
Effect of IND01 on mean pain latency (sec.) against thermal hyperalgesia in hot-plate test after SNCI in rats
Group
Mean pain latency (sec)  依  SEM
Day 0 Day 2 Day 14 Day 28
Normal 11.87 依 0.48 11.68依 0.49 10.97 依 0.34 11.40 依 0.54
Sham control 11.92 依 0.33  9.55 依 0.22 11.40 依 0.37 11.38 依 0.35
SNCI control 11.92 依 0.28        4.97 依 0.19###,$$$         5.23 依 0.07###,$$$         4.78 依 0.20###,$$$
IND01 (50)  + SNCI 11.83 依 0.34  4.67 依 0.17     6.42 依 0.20*    5.98 依 0.18*
IND01 (100)  + SNCI 12.13 依 0.34  4.97 依 0.17       8.72 依 0.20***    10.98 依 0.18***
IND01 (200)  + SNCI 12.22 依 0.31  4.95 依 0.18       8.72 依 0.20***    10.98 依 0.18***
Pyridoxine HCl (100) + SNCI 12.42 依 0.37  4.95 依 0.12       9.98 依 0.35***    11.85 依 0.30***
Data was expressed as mean pain latency in paws (in seconds) 依 SEM for six rats per group. Data was analyzed by two-way repeated measures 
ANOVA followed by post hoc Bonferroni test for comparison of groups. ### P < 0.001 as compared with normal rats. $$$ P < 0.001 as compared with 
sham control group. * P < 0.05, *** P < 0.001 as compared with SNCI control group.
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day-2, neither IND01 (50, 100 or 200 mg/kg) nor pyridoxine 
HCl (100 mg/kg) showed change in MFT score as compared 
with SNCI control rats (Table 4).
3.7. Effect on MNCV after SNCI in rats
  The MNCV in normal and sham control rats was found 
to be 52.89 and 47.58 m/s respectively on day-15 of the 
study (Table 4). SNCI control rats showed significantly
(P < 0.001) reduction in MNCV (14.58 m/s) as compared with 
normal or sham control rats (Table 4) indicating induction of 
neuropathy. MNCV of rats treated with daily oral treatment 
of IND01 (50, 100 or 200 mg/kg) or pyridoxine HCl (100 mg/kg) 
was significantly (P < 0.01) more as compared with MNCV of 
PSNL control rats (Table 4).
Table 4
Effect of IND01 on MFT score and MNCV after SNCI in rats.
Measurements after SNCI 
Mean MFT score依 SEM MNCV (m/s)
Day 15Day 0 Day 2 Day 15 Day 30
Normal 0.00 依 0.00 0.00 依 0.00 0.00 依 0.00 0.00 依 0.00 52.89 依 2.14
Sham control 0.00 依 0.00 0.27 依 0.05 0.09 依 0.03 0.10 依 0.02 47.53 依 2.21
SNCI control 0.00 依 0.00       2.92 依 0.08###,$$$       2.98 依 0.20###,$$$ 03 依 0.07###,$$$       14.58 依 0.48###,$$$
IND01 (50) + SNCI 0.00 依 0.00 3.08 依 0.15   2.66 依 0.04** 3.33 依 0.09**    22.92 依 1.60**
IND01 (100) + SNCI 0.00 依 0.00   3.1 依 0.04    1.83 依 0.09*** 1.36 依 0.04***     30.92 依 1.60***
IND01 (200) + SNCI 0.00 依 0.00 3.11 依 0.14    1.50 依 0.08*** 1.12 依 0.02***     32.01 依 1.40***
Pyridoxine HCl (100) + SNCI 0.00 依 0.00 2.98 依 0.09    1.40 依 0.03*** 1.20 依 0.04***     35.73 依 2.19***
Data was expressed as mean parameter value (in seconds) 依 SEM for six rats per group. Data for MFT was analyzed by two-way repeated 
measures ANOVA followed by post hoc Bonferroni test for comparison of groups. Data for MNCV was analyzed by one-way ANOVA followed by 
post hoc Dunnett's multiple comparison test for comparison of groups. ### P < 0.001 as compared with normal rats. $$$ P < 0.001 as compared with 
sham control group. ns - not significant,** P < 0.01, *** P < 0.001 as compared with SNCI control group.
4. Discussion 
  PSNL and SNCI are most commonly used models to induce 
neuropathy and correlated well to clinical situations[20]. 
In the present study, PSNL and SNCI showed progressive 
thermal analgesia (decrease in mean paw withdrawal 
latencies) in rats. On daily oral treatment for 7 days, IND01 
(100 and 200 mg/kg) protected the rats (with PSNL and SNCI) 
from TH and loss of motor function. 
  The deficiency of pyridoxine HCl (Vitamin B6) is known to 
cause peripheral neuropathy. Vitamin-B6 supplementation 
is proved to alleviate peripheral neuropathic pain in many 
studies in laboratory animals[21, 22] and patients[23, 24]. 
Therefore, we used pyridoxine HCl as positive control in our 
study. Pyridoxine HCl showed good neuroprotection in our 
study against PSNL and SNCI models of mononeuropathy in 
rats which is in line with our earlier finding[21].  
  TH is caused by the ectopic discharge, release of cytokines 
from the inflammatory cells around the injured nerve and 
changes in the sensory pathways to the spinal cord and 
brain[25]. Therefore, the results of present study indicated 
modulation of sensory pathway or inhibition of cytokine 
release as one of the probable mechanism of IND01 against 
TH in peripheral neuropathy. The behavioural symptoms, 
which develop simultaneously, include hyperalgesia, 
spontaneous pain, abnormal gait and weight bearing on 
the opposite side of the operated limb[26]. These symptoms 
have been reported to progress within 1-2 days post nerve 
insult[26]. In the present study, IND01 (100 and 200 mg/kg) 
showed time-dependant reduction of MFT score from day-7 
onwards.  
  Neuropathy is resulted in structural changes in peripheral 
nerves. These changes lead to endoneural edema, increased 
intraneural pressure, decreased blood flow to nerves, 
ischemia, and finally Wallerian-like axonal degeneration 
and finally decrease in MNCV[27]. IND01 in all tested doses 
(50, 100 and 200 mg/kg) restored the MNCV of rats with 
neuropathy induced by SNCI but not by PSNL, probably by of 
sciatic nerve restoration property of fenugreek[28] or neurite 
outgrowth promoting property of trigonelline[29]. 
  Tissue damage, inflammation or injury of the nervous 
system is cardinal cause of chronic neuropathic pain. In the 
past, potent antiinflammatory effects of fenugreek extract 
were attributed to alkoloidal constituents[6]. Therefore, 
marker compound, trigonelline, a major alkaloid of 
fenugreek seeds, is probably responsible for protection 
against neuronal inflammation in the present study. 
Fenugreek extract is reported to be potent analgesic agent 
through seroterngic and purinergic (P2X)[30] receptors 
involvement. P2X receptors plays an important role in 
the modulation of spinal  and peripheral nociceptive 
transmission following the development of nerve or tissue 
injury and inflammation[31]. Therefore, the analgesic effects 
of IND01 in the present study against neuropathic pain can 
be attributed to serotonergic and purinergic pathways.
  Oxidative stress, triggered by vascular abnormalities and 
associated microangiopathy, in the nerve is a key step in a 
cascade of changes leading to nerve damage[32] and leads 
to neuropathic pain. Free radicals and cytokines, that are 
responsible for cell damage, are released from neutrophils. 
The increased oxidative stress then further aggravates the 
nerve damage.  Therefore, neuroprotection observed in the 
present study is in line with the existing reports of vital 
organ protection shown by fenugreek seed extract[33, 34] 
through antioxidant mechanism[35].
  In conclusion, the present investigation suggested the 
usefulness of IND01 against neuropathic pain. Our results 
can prove to be vital step towards development of medicinal 
agent in management of peripheral neuropathic diseases 
including diabetic neuropathy, a long-term complication of 
DM.  However, further studies involving evaluation of IND01 
against neuropathic pain in diabetic animals and patients 
are suggested to substantiate such claim. 
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